# New clinical trials in Guatemala: 22 since Nov 2024

Updated October 29, 2026.

22 clinical studies with a site in Guatemala were first posted on ClinicalTrials.gov from November 20, 2024 to October 29, 2026; 11 have an industry sponsor and 17 are recruiting or about to. The newest, NCT07904767, was posted on October 29, 2026: A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in... (Aperta Biosciences, LLC).

## The full list

New clinical trials with a site in Guatemala: 22 rows for $5, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/country/guatemala

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 22
- Industry sponsored: 11
- Recruiting or not yet: 17
- Latest posted: October 29, 2026

## Newest trials

The newest 22 of 22, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07904767 | A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis | Aperta Biosciences, LLC | Phase 2 | Not yet recruiting | Blepharitis | 15 | Guatemala | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904767) |
| September 4, 2026 | NCT07804667 | Pilot Study of a Modified Therapeutic Food Compared With a Standard Nutrient Supplement in Young Children in Rural Guatemala | Wuqu' Kawoq, Maya Health Alliance | Not applicable | Not yet recruiting | Stunting of Growth, Chronic Malnutrition | 36 | Guatemala | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804667) |
| June 8, 2026 | NCT07632014 | CAYA Cancer Prospective Cohort Study | Resonance, Inc. | Observational | Recruiting | Cancer, Pediatric Cancer, Lymphoblastic Lymphoma (LBL), Acute Lymphoblastic Leukemia (ALL) | 6,000 | Armenia, Egypt, El Salvador, Guatemala, Honduras | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632014) |
| May 13, 2026 | NCT07585318 | Multi-Omic Profiling of a Zinc-Biofortified Maize Intervention in Guatemalan Mothers and Children | Institute of Nutrition of Central America and Panama | Not applicable | Completed | Zinc Deficiency, Mother and Child Malnutrition | 60 | Guatemala | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585318) |
| February 3, 2026 | NCT07383428 | The INICIO-Guatemala Study | University of North Carolina, Chapel Hill | Not applicable | Recruiting | Development, Child | 400 | Guatemala | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07383428) |
| December 10, 2025 | NCT07276022 | Laparoscopic Skills Acquisition Using an AI-enhanced Game-based Simulation Tool Compared With a Laparoscopic Simulator Box Trainer | University of Edinburgh | Not applicable | Completed | Laparoscopic Surgery | 157 | Guatemala, India, Nigeria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07276022) |
| December 5, 2025 | NCT07266831 | A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) | Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | 570 | Argentina, Canada, Chile, France, Guatemala, Mexico, South Africa, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07266831) |
| December 3, 2025 | NCT07262320 | Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America | University of Alabama at Birmingham | Observational | Recruiting | Dialysis, Critically Ill Acute Kidney Injury, Renal Replacement Therapy for Acute Kidney Injury in ICU, Acute Kidney... | 1,000 | Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guatemala... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262320) |
| November 24, 2025 | NCT07246213 | CAYA Cancer Retrospective Cohort Study | Resonance, Inc. | Observational | Recruiting | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Young Adult Cancer, Adolescent Cancer, Childhood Cancers, Acute... | 18,000 | Armenia, Egypt, El Salvador, Guatemala, Honduras, Tanzania | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246213) |
| September 24, 2025 | NCT07190248 | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 675 | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190248) |
| June 29, 2025 | NCT07044297 | A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | Merck Sharp & Dohme LLC | Phase 3 | Active not recruiting | Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | 4,390 | Argentina, Brazil, Chile, Colombia, Dominican Republic, France, Guatemala... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044297) |
| May 13, 2025 | NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms | 2,400 | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966700) |
| April 13, 2025 | NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Prostate Cancer, Prostatic Neoplasms | 1,440 | Argentina, Australia, Austria, Brazil, Chile, China, Colombia, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06925737) |
| March 3, 2025 | NCT06855108 | Caffeine for Hypoxic Ischemic Encephalopathy | NICHD Global Network for Women's and Children's Health | Phase 3 | Recruiting | Hypoxic Ischemic Encephalopathy (HIE) | 830 | Bangladesh, Democratic Republic of the Congo, Guatemala, India, Pakistan, Zambia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06855108) |
| February 11, 2025 | NCT06819878 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately... | Hoffmann-La Roche | Phase 3 | Recruiting | Moderately to Severely Active Crohns Disease | 600 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819878) |
| December 30, 2024 | NCT06751836 | Innovative Multidisciplinary Strategies for Combating Severe Dengue | Karolinska Institutet | Observational | Recruiting | DENV Without Warning Signs, DENV with Warning Signs, Severe Dengue, Healthy Controls Group - Age and Sex-matched | 1,400 | Guatemala, India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06751836) |
| December 27, 2024 | NCT06750120 | Addressing the Double Burden of Malnutrition in Guatemala | Brigham and Women's Hospital | Not applicable | Recruiting | Maternal Obesity Complicating Pregnancy, Birth,or Puerperium, Child Malnutrition | 1,532 | Guatemala | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06750120) |
| December 9, 2024 | NCT06723392 | Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries | NICHD Global Network for Women's and Children's Health | Phase 3 | Recruiting | Preterm Birth, Small for Gestational Age (SGA), Stillbirth, Bacteriuria (Asymptomatic) in Pregnancy | 1,134 | Bangladesh, Democratic Republic of the Congo, Guatemala, India, Pakistan, Zambia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06723392) |
| December 6, 2024 | NCT06720896 | A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001... | Aperta Biosciences, LLC | Phase 2 | Completed | Blepharitis | 66 | Guatemala | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06720896) |
| December 5, 2024 | NCT06717347 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP)... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Diffuse Large B-Cell Lymphoma | 1,046 | Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06717347) |
| December 2, 2024 | NCT06711887 | Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus... | Novartis Pharmaceuticals | Phase 3 | Recruiting | Lupus Nephritis | 348 | Brazil, China, Colombia, Czechia, France, Guatemala, Hong Kong, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06711887) |
| November 20, 2024 | NCT06698042 | A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer... | Merck Sharp & Dohme LLC | Phase 3 | Active not recruiting | Lung Cancer, Non-Small Cell Lung Cancer | 67 | China, Germany, Guatemala, Japan, Peru, Poland, Romania, South Korea, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06698042) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Merck Sharp & Dohme LLC | 7 | December 5, 2025 |
| Aperta Biosciences, LLC | 2 | October 29, 2026 |
| Resonance, Inc. | 2 | June 8, 2026 |
| NICHD Global Network for Women's and Children's Health | 2 | March 3, 2025 |
| Wuqu' Kawoq, Maya Health Alliance | 1 | September 4, 2026 |
| Institute of Nutrition of Central America and Panama | 1 | May 13, 2026 |
| University of North Carolina, Chapel Hill | 1 | February 3, 2026 |
| University of Edinburgh | 1 | December 10, 2025 |
| University of Alabama at Birmingham | 1 | December 3, 2025 |
| Hoffmann-La Roche | 1 | February 11, 2025 |
| Karolinska Institutet | 1 | December 30, 2024 |
| Brigham and Women's Hospital | 1 | December 27, 2024 |
| Novartis Pharmaceuticals | 1 | December 2, 2024 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| Blepharitis | 2 | October 29, 2026 |
| [Neoplasms](https://specstream.ai/data/clinical-trials/condition/neoplasms) | 2 | June 8, 2026 |
| [Precursor Cell Lymphoblastic Leukemia-Lymphoma](https://specstream.ai/data/clinical-trials/condition/precursor-cell-lymphoblastic-leukemia-lymphoma) | 2 | June 8, 2026 |
| Child Nutrition Disorders | 2 | May 13, 2026 |
| [Acquired Immunodeficiency Syndrome](https://specstream.ai/data/clinical-trials/condition/acquired-immunodeficiency-syndrome) | 2 | December 5, 2025 |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 2 | September 24, 2025 |
| Iron Deficiencies | 1 | May 13, 2026 |
| [Infections](https://specstream.ai/data/clinical-trials/condition/infections) | 1 | December 5, 2025 |
| [Acute Kidney Injury](https://specstream.ai/data/clinical-trials/condition/acute-kidney-injury) | 1 | December 3, 2025 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 1 | May 13, 2025 |
| [Triple Negative Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/triple-negative-breast-neoplasms) | 1 | May 13, 2025 |
| Parkinson Disease 4, Autosomal Dominant Lewy Body | 1 | May 13, 2025 |
| [Prostatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/prostatic-neoplasms) | 1 | April 13, 2025 |
| Hypoxia-Ischemia, Brain | 1 | March 3, 2025 |
| Severe Dengue | 1 | December 30, 2024 |
| Growth Disorders | 1 | December 27, 2024 |
| Pregnancy in Obesity | 1 | December 27, 2024 |
| [Premature Birth](https://specstream.ai/data/clinical-trials/condition/premature-birth) | 1 | December 9, 2024 |
| Stillbirth | 1 | December 9, 2024 |
| Bacteriuria | 1 | December 9, 2024 |
| [Lymphoma, Large B-Cell, Diffuse](https://specstream.ai/data/clinical-trials/condition/lymphoma-large-b-cell-diffuse) | 1 | December 5, 2024 |
| Lupus Nephritis | 1 | December 2, 2024 |
| [Lung Neoplasms](https://specstream.ai/data/clinical-trials/condition/lung-neoplasms) | 1 | November 20, 2024 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 10 | September 24, 2025 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 5 | September 4, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 4 | June 8, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 2 | October 29, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 1 | December 5, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).